Agoracom Blog Home

Posts Tagged ‘Marijuana’

VIDEO – With $17M In Profitable Cannabis Revenues Already, The Latest Kiaro Acquisitions Are Expected To Create $43M In Revenue & $13.7M Gross Profit

Posted by AGORACOM-JC at 4:54 PM on Friday, July 16th, 2021
Kiaro holdings corp  kiaro completes kelowna cannabis retail loc

Kiaro Holdings is an multi-channel cannabis retailer and distributor with existing storefronts across British Columbia , Saskatchewan and Ontario, a wholesale distribution servicing Saskatchewan and ecommerce sites in Canada , the US and Australia, which have resulted in the following:

  • ANNUAL REVENUE              $17.1M Up 230%
  • ANNUAL GROSS PROFIT     $5.1M Up 281%  
  • Q1 REVENUE                          $5.2M Up 94%
  • Q1 GROSS PROFIT                 $1.56M Up 118%

But CEO Daniel Petrov and his team of retail winners aren’t stopping there. On July 13th, $KO announced  Kiaro Acquires Hemisphere Cannabis and Adds 7 Retail and 2 Development Locations in Ontario To Become a Prominent National Cannabis Retailer with Forecasted Annual Revenues of $42.7 Million.

If you believe in the long-term future of the cannabis market, then you have to discover KIARO by watching our first ever interview with CEO Daniel Petrov.

VIDEO – Harborside $HBOR.ca $HBORF Developing Operational Scale as 2020 Gross Revenues Expand 29% to $63M $VFF.to $HARV.ca $ACB.to

Posted by AGORACOM-Eric at 9:09 AM on Thursday, June 24th, 2021

Harborside Inc. is one of the oldest and most respected cannabis retailers in California, operating three of the major dispensaries in the San Francisco Bay Area and a cultivation/production facility in Salinas, California and awarded one of the first six medical cannabis licenses granted in the United States.

Harborside hold cannabis licenses for retail, distribution, cultivation, nursery, and manufacturing.

With California being one of the largest cannabis markets in the world, Harborside Retail operations command 3% of California’s entire retail market and operations have generated over $400M in cumulative sales since inception

Fourth Quarter and Full Year 2020 Financial Results

Full Year 2020 Gross Revenues Expand 29% Year-Over-Year to $63.4 Million Full Year

2020 Adjusted EBITDA grows to $7.4 Million From an Adjusted EBITDA Loss of $8.9 Million in 2019(1)

Reports Fourth Quarter Gross Revenues of $13.1 Million and Positive Adjusted EBITDA of $0.7 Million(1)

Fourth Quarter Total Gross Margins improved from 22.1% to 49.9%(1), Driven by Improved Harvest Yields, Higher Wholesale Volumes, and Improved Operating Leverage Supported by Tight Expense Management

2020 Operational Highlights

Closed upsized private placement for gross proceeds of approximately C$35.1 million

Secured a $12 million revolving credit facility

Completed a $5 million strategic investment in Loudpack, a premier California cannabis company

Completed the acquisition of a 21% interest in a San Francisco Dispensary in the historic Haight-Ashbury District

Sit back, relax and watch this powerful interview with Matt hawkins as he demonstrates the powerful growth potential legislation is anticipated to have on operations.

Spyder Cannabis $SPDR Acquires Leading Vape Retailer 180 Smoke $FAF $FAF.ca $CLIQ $ISH $ISH.ca $SUN.ca

Posted by AGORACOM-JC at 8:44 AM on Wednesday, March 31st, 2021
  • Announce the closing of its previously announced acquisition on February 23, 2021 of all of the issued and outstanding shares of the entities that collectively comprise the business of 180 Smoke

Vaughan, Ontario–(March 31, 2021) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company“), an established Canadian cannabis and vape retailer, is pleased to announce the closing of its previously announced acquisition on February 23, 2021 of all of the issued and outstanding shares of the entities that collectively comprise the business of 180 Smoke (“180 Smoke“), a dominant vape retailer in Canada. On March 30, 2021, the Company purchased all of the shares of 180 Smoke (the “Acquisition“) from CRHC Holdings Corp. (the “Seller“), on a cash-free basis (after post-closing adjustments), for nominal consideration. Additionally, the Company secured a strategic institutional investor to lead the acquisition of all the existing debt of 180 Smoke owing to an affiliate of the Seller.

Dan Pelchovitz, President & CEO of Spyder, commented, “We are extremely excited to welcome 180 Smoke to the Spyder team, which undoubtedly strengthens our management and operating teams bringing strong retail processes and expertise to Spyder. The acquisition of 180 Smoke significantly accelerates the development of Spyder’s cannabis and vape retail growth strategy, providing access to an iconic brand name, an established platform, and a loyal customer base. We are excited by the prospects ahead of us and executing on our immediate cannabis retail expansion plans in Ontario.”

Transaction Highlights

  • 180 Smoke is a leading Canadian vape product retailer that has been widely regarded as the gold standard for vape store operations and customer service. 180 Smoke sells high-quality e-cigarettes, vaporizers and other nicotine-related products.
  • The Acquisition is expected to immediately increase Spyder’s consolidated revenue with the addition of 180 Smoke’s nicotine vape sales, franchise revenue and other wholesale and distribution revenue which generated approximately $12.9 million in unaudited net revenue with gross margins of 50% during the year ended December 31, 2020.
  • 180 Smoke has a team of 91 employees who will continue to operate 180 Smoke’s 18 brick and mortar vape retail locations, 8 franchises, and its corporate head office and distribution warehouse, following the closing of the Acquisition.
  • 180 Smoke’s current customer base includes 92,481 in-store accounts, 98,052 online accounts, as well as 235 specialty wholesale vape B2B accounts.
  • Immediately after closing, Spyder expects to integrate its 2 brick and mortar vape retail stores with those of 180 Smoke’s to leverage the acquired know-how and intellectual property, including retail store design and layout, standard operating procedures, administrative systems and customer support, human resources and staff training, and accounting.
  • Synergies are also expected between 180 Smoke’s existing customer base with Spyder’s cannabis business.
  • Spyder will have the ability to utilize its wholly-owned subsidiary’s Retail Operator License issued by the Alcohol and Gaming Commission of Ontario (AGCO) to convert some of 180 Smoke’s existing vape retail locations to licensed cannabis dispensaries by obtaining a Retail Store Authorization from the AGCO for such store.

Quizam Media Corp $QQ.ca $QQQFF is Seeing Explosive Growth for its Quantum #Cannabis Corporation, Expanding its Retail Footprint amidst The Great Cannabis Gold Rush $FAF $FAF.ca $CLIQ $ISH $ISH.ca $SUN.ca

Posted by AGORACOM-JC at 5:01 PM on Wednesday, March 3rd, 2021

Quizam Media Corp’s (QQ:CSE QQQFF:OTC) wholly owned subsidiary Quantum 1 Cannabis is experiencing rapid growth across British Columbia!

In the past 12 months, Quantum 1 has opened stores in:

  • North Vancouver
  • Vernon
  • Grand Forks
  • Keremeos
  • Creston

And it will soon be opening its sixth, and flagship, store in Oakridge, B.C.

In Tandem with this expansion, quarterly revenue is accelerating rapidly, rising from $138,000 in Nov 2019 to $954,000 in Nov 2020.

What’s its secret sauce? The company places a huge emphasis on education. That’s because Quizam has its roots as an educational media company that spent a long time educating people about cannabis, long before it became legal.

  • In this nascent market, people are looking for trusted, authoritative voices

The company’s growth comes as Canada is experiencing ‘The Great Cannabis Gold Rush’ –

  • By 2021, Canada’s cannabis market is expected to reach $3bn, translating to 77.9% CAGR from 2018-2021.
  • Cannabis now contributes $14.6bn to Canada’s economy, up from $8bn previous est.
  • Cannabis 2.0 new products (candy, drinks) could generate $2.5bn in sales in Canada.
  • You’re going to want to get comfy for this conversation with Russ Rossi, Quizam Media’s President & CEO:

Spyder $SPDR.ca Cannabis to Acquire a Leading Vape Retailer 180 Smoke $ACB $APHA $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 11:23 AM on Tuesday, February 23rd, 2021
  • To acquire all of the issued and outstanding shares of the entities that collectively comprise the business of 180 Smoke (“180 Smoke“), a dominant vape retailer in Canada. The Company has agreed to purchase the shares of 180 Smoke

Vaughan, Ontario–(February 23, 2021) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company“), an established Canadian cannabis and vape retailer, is pleased to announce that the Company has entered into a binding agreement with CRHC Holdings Corp. (the “Seller“) to acquire all of the issued and outstanding shares of the entities that collectively comprise the business of 180 Smoke (“180 Smoke“), a dominant vape retailer in Canada. The Company has agreed to purchase the shares of 180 Smoke (the “Acquisition“), on a cash-free basis (after post-closing adjustments), for nominal consideration. Additionally, the Company has secured a strategic institutional investor to acquire all of the existing debt of 180 Smoke owing to an affiliate of the Seller. The parties will proceed to close the Acquisition upon satisfaction of the closing conditions.

Transaction Highlights

  • 180 Smoke is a leading Canadian vape product retailer that has been widely regarded as the gold standard for vape store operations and customer service. 180 Smoke sells high-quality e-cigarettes, vaporizers and other nicotine-related products.
  • The Acquisition is expected to immediately increase Spyder’s consolidated revenue with the addition of 180 Smoke’s nicotine vape sales, franchise revenue and other wholesale and distribution revenue which generated approximately $12.9 million in unaudited net revenue during the year ended December 31, 2020.
  • 180 Smoke has a team of 91 employees who will continue to operate 180 Smoke’s 18 brick and mortar vape retail locations, 8 franchises, and its corporate head office and distribution warehouse, following the closing of the Acquisition.
  • 180 Smoke’s current customer base includes 92,481 in-store accounts, 98,052 online accounts, as well as 235 specialty wholesale vape B2B accounts.
  • Spyder expects to integrate its 2 brick and mortar vape retail stores with those of 180 Smoke’s to leverage the acquired know-how and intellectual property, including retail store design and layout, standard operating procedures, administrative systems and customer support, human resources and staff training, and accounting.
  • Synergies are also expected between 180 Smoke’s existing customer base with Spyder’s cannabis business.
  • Spyder will have the ability to utilize its wholly-owned subsidiary’s Retail Operator License issued by the Alcohol and Gaming Commission of Ontario (AGCO) to convert some of 180 Smoke’s existing vape retail locations to licensed cannabis dispensaries by obtaining a Retail Store Authorization from the AGCO for such store.

Read More: https://agoracom.com/ir/SpyderCannabis/forums/discussion/topics/755908-spyder-cannabis-to-acquire-a-leading-vape-retailer-180-smoke/messages/2304946#message

Spyder Cannabis Provides Update on Cannabis Dispensary Application in Pickering $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 9:00 AM on Tuesday, February 16th, 2021
  • Received notice from the City of Pickering regarding an initial inspection of the Company’s proposed cannabis dispensary located at 776 Liverpool Rd., Unit 4, Pickering, Ontario, L1W 1S2.
  • Spyder Subco has a Retail Operator License issued by the Alcohol and Gaming Commission of Ontario and currently operates a cannabis dispensary in Niagara Falls, Ontario.

Vaughan, Ontario–(February 16, 2021) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company“), an established Canadian cannabis and vape retailer, is pleased to announce that its wholly-owned subsidiary, Spyder Cannabis Subco Inc. (“Spyder Subco“), has received notice from the City of Pickering regarding an initial inspection of the Company’s proposed cannabis dispensary located at 776 Liverpool Rd., Unit 4, Pickering, Ontario, L1W 1S2. Spyder Subco has a Retail Operator License issued by the Alcohol and Gaming Commission of Ontario (the “AGCO“) and currently operates a cannabis dispensary in Niagara Falls, Ontario.

In anticipation of the city’s approval of the sale of cannabis in Pickering, the Company secured a retail premises and began to build out the location in 2019. The inspection is scheduled to take place during the week of February 16, 2021. Subject to passing the inspection, and making any necessary modifications, Spyder Subco will be placed in the queue of applications and will await receipt of a Retail Store Authorization from the AGCO for the new premises, permitting the Company to begin operating a licensed cannabis dispensary in Pickering and its second dispensary in Ontario.

Dan Pelchovitz, President & CEO of Spyder, commented, “Pickering is strategically located where Toronto, York and Durham Regions meet, and boasts a growing population of approximately 100,000 residents. Spyder’s team is excited to bring its brand name and best-in-class customer service to one of the fastest growing cities in Ontario.”

Read More: https://agoracom.com/ir/SpyderCannabis/forums/discussion/topics/755397-spyder-cannabis-provides-update-on-cannabis-dispensary-application-in-pickering/messages/2303797#message

Avicanna $AVCN.ca $AVCNF Enters Multi-level Strategic Partnership with Al Harrington’s, Harrington Wellness Inc., to Commercialize re+PLAY™ Branded Products in Canada $WEED.ca $CL.ca $HEXO.ca

Posted by AGORACOM-JC at 8:46 AM on Tuesday, February 9th, 2021
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Development and licensing of a bespoke and evidence-based athletic line of CBD topical products for the re+PLAY brand in the U.S.
  • Avicanna to lead commercialization in Canada through consumer retail and medical sales channels.

TORONTO, Feb. 09, 2021 — Avicanna Inc. (“ Avicanna ” or the “ Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that the Company has entered into an intellectual property licensing and royalty agreement with Harrington Wellness Inc. (“ Harrington Wellness” ) for the commercialization of a CBD topical product line targeting athletes and active consumers in Canada and the U.S. (the “ re+PLAY Agreement ”). 

Avicanna and Harrington Wellness have worked together extensively on researching, developing and optimizing a bespoke line of CBD-based topicals designed specifically for the athletic and sports community (the “ re+PLAY Products” ). These CBD-based topicals utilize Avicanna’s proprietary deep tissue technology for cannabinoid delivery and have been curated with the support of Harrington Wellness’ deep understanding of the needs of professional athletes. The products are planned to be launched in Q2 2021 in the United States by Harrington Wellness across retail and e-commerce channels and in Canada through medical and adult-use/consumer retail cannabis sales channels by Avicanna. The product formulations are also enrolled in several preclinical studies with leading Canadian medical institutions to assess their efficacy in chronic pain and osteoarthritis. 

Under the re+PLAY Agreement, which has an initial three-year term, Avicanna has licensed the use of certain proprietary product formulations to Harrington Wellness to be used in connection with the manufacture and distribution of the re+PLAY Products in the United States. Additionally, Harrington Wellness has also licensed the use of the re+PLAY brand to Avicanna to be used in connection with the manufacture and distribution of the re+PLAY Products in Canada. The re+PLAY Products will be branded and sold under the re+PLAY brand in both the United States and Canada. Royalties are payable to Avicanna and Harrington Wellness as consideration for each of the licenses. 

“As a former professional athlete myself and avid CBD user, I understand the importance of being in peak physical condition and finding products that help you to recover faster,” says Al Harrington, CEO of Harrington Wellness. “Avicanna has been an incredible partner in developing the re+PLAY formulas and expanding the product line’s availability into Canada.” 

In commenting on the re+PLAY Agreement, Aras Azadian, CEO of Avicanna said, “I am thrilled to finally introduce our relationship with Al Harrington and Harrington Wellness. This partnership was formed on the alignment of the vision to introduce premium and scientifically backed products for athletic and active consumers to the market. Additionally, the distinct expertise of the two companies and collaborative spirit has yielded an advanced and evidence-based line of products that are tailored to promote a healthy active lifestyle for the athlete in all of us.” 

To the knowledge of the Company, it is in compliance with all applicable laws in the jurisdictions in which it operates. 

About Harrington Wellness  

Founded in 2018 by Viola CEO and NBA Vet, Al Harrington, Harrington Wellness produces a wide range of products via in house manufacturing, joint venture projects and white label arrangements with other vetted organizations that stand for the highest quality and reliable medical benefits. These items are sold online via in house and existing marketplace sites, in brick and mortar retail and by health professions directly in their clinics. 

Harrington Wellness’ hero brand, re+PLAY™ is a performance based CBD wellness brand created with the combined knowledge and experience of athletes, doctors, and certified athletic trainers. Our team is dedicated to creating best in class products that deliver the powerful healing properties of the plant to our customers. All products are made using a triple-tested process with hemp grown in the USA, and are free of heavy metals, pesticides, and harmful microbes. 

Read More: https://agoracom.com/ir/Avicanna/forums/discussion/topics/754961-avicanna-enters-multi-level-strategic-partnership-with-al-harrington-s-harrington-wellness-inc-to-commercialize-re-play-branded-products-in-canada/messages/2302800#message

Avicanna $AVCN.ca $AVCNF Launches RHO Phyto™ Topical Gels in Canada and Initiates Clinical Studies $TRUL.ca $ACB

Posted by AGORACOM-JC at 7:59 AM on Thursday, January 28th, 2021
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • RHO Phyto Deep Tissue Gels will be initially available on the Medical Cannabis by Shoppers Drug Mart™ online platform and expanded into specific consumer retail channels in February 2021.
  • Initiation of osteoarthritis preclinical trials in Canada in addition to the enrollment of the products into the UHN MC-RWE study to evaluate the effectiveness on pain, sleep, anxiety, and depression.

TORONTO, Jan. 28, 2021 — Avicanna Inc. (“ Avicanna ” or the “ Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce the launch of the RHO Phyto™ Deep Tissue Gels (the “ RHO Phyto Deep Tissue Gels ”) through Medical Cannabis by Shoppers Drug Mart as well as through additional adult use channels. The Company is also pleased to announce the initiation of pre-clinical osteoarthritis evaluations after successful in vitro studies and the enrollment of the Deep Tissue Gels in the Medical Cannabis Real World Evidence (“ MC-RWE ”) study. The MC-RWE study is led by the University Health Network (“ UHN ”) with the goal to evaluate the effectiveness of medical cannabis on pain, sleep and other related comorbidities.

About the RHO Phyto Deep Tissue Gels

The RHO Phyto Deep Tissue Gels synergistically combine natural clove oil and menthol with cannabinoids and natural polyphenols in advanced emulsions which are optimized for faster absorption and deeper delivery. The RHO Phyto Deep Tissue Gel formulations are also designed for long term cannabinoid shelf-life stability and accurate dosing with cooling sensation, and pleasant mint aroma. The deep tissue technology has been developed and optimized by Avicanna’s research and development team. Over the last 3 years, the RHO Phyto Deep Tissue Gel formulations have been validated by a series of preclinical studies where both stability and enhanced absorption into the deeper layers of the skin were shown.

Read More: https://agoracom.com/ir/Avicanna/forums/discussion/topics/754105-avicanna-launches-rho-phyto-topical-gels-in-canada-and-initiates-clinical-studies/messages/2300727#message

Avicanna $AVCN.ca $AVCNF Initiates Pre-Clinical and Behavioural Studies on its RHO Phyto™ Formulary with University of Guelph and Provides Research and Management Team Updates $WEED.ca $CL.ca $HEXO.ca

Posted by AGORACOM-JC at 8:07 AM on Thursday, January 21st, 2021
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Updated and amended its collaboration with Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, and initiated prioritized pre-clinical studies on the RHO Phyto formulations that are commercialized in Canada and Colombia.
  • Additionally, the Company provides an update on research projects with the University of Toronto and Thompson Rivers University as well as a change to its management team.

TORONTO, Jan. 21, 2021– Avicanna Inc. (“ Avicanna ” or the “ Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products has updated and amended its collaboration with Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, and initiated prioritized pre-clinical studies on the RHO Phyto formulations that are commercialized in Canada and Colombia. Additionally, the Company provides an update on research projects with the University of Toronto and Thompson Rivers University as well as a change to its management team.

Initiation of pre-clinical studies on RHO Phyto in collaboration with University of Guelph

Further to Avicanna’s previous announcement regarding Dr. Khokhar’s research team at the University of Guelph being awarded a Natural Sciences and Engineering Research Council of Canada (“ NSERC ”) Alliance grant focused on the neurobiological underpinnings of cannabis toxicosis with the aim to evaluate Avicanna’s formulations in the treatment of cannabis-induced toxicosis, the project is now being expanded. The expansion of the project includes pharmacokinetic and behavioural testing of Avicanna’s RHO Phyto™ formulations as well as studying their efficacy in alleviating neuropathic pain and addiction. The data generated from the research will help guide Avicanna’s clinical development, including the pharmaceutical and real-world evidence studies related to the RHO Phyto formulations, and will provide additional information to health care practitioners who are recommending and prescribing the products in several markets.

COVID-19 drug candidate project update

The research collaboration with the University of Toronto on the development of a drug candidate to treat lung inflammation caused by COVID-19, with funding support from an NSERC Alliance grant and a MITACS Alliance grant, is complete. The peer-reviewed grants were focused on the development of a cannabinoid formulation to be used for further research on COVID-19. The physical and chemical characterization of the optimized cannabinoid formulation is complete, which included its stability and drug release properties in relevant conditions.

COVID-19 and anti-inflammatory related research collaboration with TRU with non-dilutive funding

In partnership with Avicanna, Dr. Kingsley Donkor and collaborators from Thompson Rivers University (” TRU ”), will be evaluating naturally derived cannabinoids and candidate formulations for their efficacy to modulate the receiving receptor of COVID-19 (angiotensin-converting ACE2 gene expression). This project will focus on elucidating the mechanism of action of novel prophylactic nasal and oral cannabinoid products for humans that target ACE2 viral gateways. Candidate formulations, once identified, will be evaluated for anti-inflammatory effects in human-derived lung tissue models. The research with TRU is supported by an NSERC grant and a MITACS Internship.

Read More: https://agoracom.com/ir/Avicanna/forums/discussion/topics/753556-avicanna-initiates-pre-clinical-and-behavioural-studies-on-its-rho-phyto-formulary-with-university-of-guelph-and-provides-research-and-management/messages/2299215#message

Avicanna $AVCN.ca $AVCNF Advances #Pharmaceutical Epilepsy Program With Collaboration With the University Health Network and GMP Manufacturing of its First Pharmaceutical Preparation $GWPH $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 8:29 AM on Wednesday, January 6th, 2021
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Avicanna Advances Pharmaceutical Epilepsy Program With Collaboration With the University Health Network and GMP Manufacturing of its First Pharmaceutical Preparation
  • The multi-level cannabinoid-based collaboration with leading epilepsy researcher Dr. Peter Carlen at the world-renowned Krembil Research Institute at UHN is also supported by a Mitacs Accelerate program grant.
  • UHN scientists will be analyzing Avicanna’s RHO Phyto™ cannabinoid-based products for their efficacy on comorbidities and seizure control in addition to identifying optimized cannabinoid and non-cannabinoid ratios for future drug development.
  • First fully GMP and ICH compliant manufacturing of Avicanna’s proprietary pharmaceutical preparation to treat epilepsy has been completed by Altea Farmaceutica S.A. in preparation for registration and commercialization in South America.

TORONTO, Jan. 06, 2021 — Avicanna Inc. (“ Avicanna ” or the “ Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that the Company has entered into a master services agreement (the “ Master Services Agreement) with the University Health Network (“ UHN ”) for projects to be performed by Dr. Peter Carlen as the principal investigator related to epilepsy. Additionally, the company has completed the technical transfer and first pharmaceutical pilot production of its epilepsy drug candidate at Altea Farmaceutica S.A. (“ Altea ”) in Bogota, Colombia, a major step required for the final preparation for its registration and commercialization in South America.

Read More: https://agoracom.com/ir/Avicanna/forums/discussion/topics/752408-avicanna-advances-pharmaceutical-epilepsy-program-with-collaboration-with-the-university-health-network-and-gmp-manufacturing-of-its-first/messages/2296217#message